Skip to main content
Erschienen in: International Journal of Hematology 2/2010

01.03.2010 | Letter to the Editor

Development of Kaposi’s sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient

verfasst von: Alastair B. Law, Gail Ryan, Stephen Lade, H. Miles Prince

Erschienen in: International Journal of Hematology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Excerpt

We read with interest the report in this journal about HHV8-positive, HIV-negative multicentric Castleman’s disease (MCD) with early and sustained complete remission with rituximab therapy without reactivation of Kaposi’s sarcoma (KS) [ 1]. Unlike their report, we report a patient with HIV-negative MCD who was successfully treated with rituximab-based therapy, but who shortly after completion of treatment developed aggressive KS. …
Literatur
1.
Zurück zum Zitat Nicoli P, Familiari U, Bosa M, Allice T, Mete F, Morotti A, et al. HHV8-positive HIV-negative multicentric Castleman’s disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. Int J Hematol. 2009;90:392–6. CrossRefPubMed Nicoli P, Familiari U, Bosa M, Allice T, Mete F, Morotti A, et al. HHV8-positive HIV-negative multicentric Castleman’s disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. Int J Hematol. 2009;90:392–6. CrossRefPubMed
2.
Zurück zum Zitat Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1276–80. PubMed Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1276–80. PubMed
5.
Zurück zum Zitat Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol. 2008;32(7):1006–12. CrossRefPubMed Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol. 2008;32(7):1006–12. CrossRefPubMed
6.
Zurück zum Zitat Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007;147(12):836–9. PubMed Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007;147(12):836–9. PubMed
7.
Zurück zum Zitat Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS. 2009;4(1):16–21. CrossRefPubMed Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS. 2009;4(1):16–21. CrossRefPubMed
8.
Zurück zum Zitat Pastor MA, Vasco B, Mosquera JM, Debén G, Bautista P, Requena. Two HHV8-related illnesses in a HIV-negative patient: Kaposi’s sarcoma and multicentric Castleman’s disease. Response to treatment with Rituximab and CHOP. Acta Dermosifiliogr. 2006;97(6):385–90. Pastor MA, Vasco B, Mosquera JM, Debén G, Bautista P, Requena. Two HHV8-related illnesses in a HIV-negative patient: Kaposi’s sarcoma and multicentric Castleman’s disease. Response to treatment with Rituximab and CHOP. Acta Dermosifiliogr. 2006;97(6):385–90.
9.
Zurück zum Zitat Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, et al. Rituximab therapy for HIV-associated Castleman disease. Blood. 2003;102(8):2786–8. CrossRefPubMed Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, et al. Rituximab therapy for HIV-associated Castleman disease. Blood. 2003;102(8):2786–8. CrossRefPubMed
10.
Zurück zum Zitat Clifford KS, Demierre MF. Progression of classic Kaposi’s sarcoma with rituximab. J Am Acad Dermatol. 2005;53:155–7. CrossRefPubMed Clifford KS, Demierre MF. Progression of classic Kaposi’s sarcoma with rituximab. J Am Acad Dermatol. 2005;53:155–7. CrossRefPubMed
11.
Zurück zum Zitat Bollen J, Polstra A, Van Der Kuyl A, Weel J, Noorduyn L, Van Oers M, et al. Multicentric Castleman’s disease and Kaposi’s sarcoma in a cyclosporin treated, HIV-1 negative patient: case report. BMC Blood Disord. 2003;3(1):3. CrossRefPubMed Bollen J, Polstra A, Van Der Kuyl A, Weel J, Noorduyn L, Van Oers M, et al. Multicentric Castleman’s disease and Kaposi’s sarcoma in a cyclosporin treated, HIV-1 negative patient: case report. BMC Blood Disord. 2003;3(1):3. CrossRefPubMed
12.
Zurück zum Zitat Stebbing J, Gazzard B, Newsom-Davis T, Nelson M, Patterson S, Gotch F, et al. Nadir B cell counts are significantly correlated with the risk of Kaposi’s sarcoma. Int J Cancer. 2004;108:473–4. CrossRefPubMed Stebbing J, Gazzard B, Newsom-Davis T, Nelson M, Patterson S, Gotch F, et al. Nadir B cell counts are significantly correlated with the risk of Kaposi’s sarcoma. Int J Cancer. 2004;108:473–4. CrossRefPubMed
Metadaten
Titel
Development of Kaposi’s sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient
verfasst von
Alastair B. Law
Gail Ryan
Stephen Lade
H. Miles Prince
Publikationsdatum
01.03.2010
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 2/2010
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0497-9

Weitere Artikel der Ausgabe 2/2010

International Journal of Hematology 2/2010 Zur Ausgabe

Update Onkologie

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.